Compare FuelCell Energy Inc (FCEL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FuelCell Energy Inc vs Zimmer Biomet Holdings Inc — how do they compare? FuelCell Energy Inc trades at $17.65 (market cap $1.47B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.88B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 11.5× FuelCell Energy Inc's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while FuelCell Energy Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold FuelCell Energy Inc for 48 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| FCEL | ZBH | |
|---|---|---|
Market Cap | $1.47B | $16.88B |
Volume | 12,559,948 | 1,991,354 |
Sector | Industrials | Health |
52-Week High | $36.01 | $103.98 |
52-Week Low | $6.00 | $79.58 |
Typical Hold Time | 48 Days | 89 Days |
Enterprise Value | $1.05B | $23.95B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FuelCell Energy (FCEL) trades at $17.245, down 16.49% over 24 hours, reflecting recent volatility amid a securities class action. The stock shows a bullish technical signal with support near $17 and resistance at $19. Fundamentally, the company reported revenue of $158.16 million for 2025 but posted a net loss of $187.90 million, with negative profit margins persisting. Cash flow improved in 2025 with net cash flow of $132.91 million, though operational cash flow remains negative.
The outlook is cautious; while analyst consensus suggests a $21.57 price target with 40% buy ratings, ongoing legal challenges and consistent losses pose significant risks. Investment opportunity hinges on execution turnaround and market adoption of hydrogen energy, but high volatility and financial instability warrant careful consideration.
Zimmer Biomet (ZBH) trades at $88.91, down 0.86% on the day, with a bearish technical signal from moving averages. The company reported revenue of $8.23B in 2025, with net income of $705.1M, and has beaten EPS estimates for the last three quarters. Recent news highlights a quarterly dividend declaration and leadership promotions aimed at accelerating commercial transformation.
The outlook is mixed: strong fundamentals and consistent earnings beats support growth, but technical indicators and rising debt-to-asset ratios pose risks. Analyst consensus suggests a 16% upside to the $103.11 price target, though nearly half of analysts recommend Hold. Key risks include competitive pressures and execution of the company's strategic initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FuelCell Energy Inc
FuelCell Energy Inc is a fuel-cell power company. FuelCell designs manufactures, sells, installs, operates, and services fuel cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions. It serves various industries such as Industrial, Wastewater treatment, Commercial and Hospitality, Data centers and Communications, Education and Healthcare, and others. Geographically, the company generates a majority of its revenue from the United States followed by South Korea.
Read more on FCEL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
